EXAS - CIK 0001124140
EXACT SCIENCES CORP trades as EXAS and has a market capitalization of $20.03 B, making it the #619 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $3.25B, up 17.7% from the prior year and net income of -$207.95M. This page tracks EXACT SCIENCES CORP through 1,834 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years EXACT SCIENCES CORP's revenue grew from $99.38M to $3.25B, a compound annual growth rate of 47.3%. Net profit margin expanded from -168.3% to -6.4% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| 15-12G | - | 2026-04-02 |
| SCHEDULE 13G/A | - | 2026-03-26 |
| Delisting notice | 25-NSE | 2026-03-23 |
| POSASR | - | 2026-03-23 |
| S-8 POS | - | 2026-03-23 |
| S-8 POS | - | 2026-03-23 |
| S-8 POS | - | 2026-03-23 |
| S-8 POS | - | 2026-03-23 |
Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026
Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year
Select to view the solutions available in your location.
Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway
Oncotype DX Breast Recurrence Score Test Surpasses 2 Million Patients Worldwide
The largest companies sharing EXACT SCIENCES CORP's SEC industry classification (services-medical laboratories).
EXACT SCIENCES CORP (EXAS) has a market capitalization of $20.03 B as of 2026-05-29, ranking #619 among US-listed companies.
EXACT SCIENCES CORP reported revenue of $3.25B for fiscal year 2025, an increase of 17.7% year over year.
In its latest fiscal year EXACT SCIENCES CORP reported a net loss of $207.95M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.